DEVELOPING THE NEXT GENERATION OF TREATMENTS FOR CARDIOVASCULAR DISEASES.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $193M
Founded date: 2015
Investors 3
| Date | Name | Website |
| - | 5AM Ventur... | 5amventure... |
| 15.01.2022 | Omega Fund... | omegafunds... |
| - | Sofinnova ... | sofinnova.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 12.10.2021 | Series B | $143M | - |
| 17.05.2019 | Series A | $50M | - |
Mentions in press and media 18
| Date | Title | Description |
| 09.01.2023 | AstraZeneca acquire CinCor for cardiorenal asset | AstraZeneca acquire CinCor for cardiorenal asset Mon, Jan 09, 2023 08:00 CET Report this content 9 January 2023 07:00 GMT AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline Acquisition to access global rights to baxdros... |
| 28.11.2022 | CinCor Pharma Announces Topline Data for Phase 2 HALO Trial Evaluating Selective Aldosterone Synthase Inhibitor Baxdrostat in Uncontrolled Hypertension | /EIN News/ -- Primary endpoint in Intention to Treat (ITT) was not met despite large absolute reductions in Systolic Blood Pressure (SBP) 12.6 mmHg placebo-adjusted reduction in SBP with 2 mg baxdrostat in a pre-specified subgroup that repr... |
| 28.11.2022 | CinCor Hypertension Drug Flunks Study, But the Biotech Still Sees a Phase 3 Path | A CinCor Pharma drug intended to offer a novel alternative to currently available hypertension treatments has failed a Phase 2 study. Nevertheless, CinCor points to better results in a pre-specified subgroup of patients representative of ma... |
| 11.08.2022 | Just months after layoffs and pushing eye therapy, ProQR offloads eye portfolio in pivot to RNA-editing | Nearly four months after joining dozens of other biotechs in laying off employees and trimming down its pipeline, ProQR is back at it again. The Dutch biotech announced early Thursday that it will be looking for a partner to t... |
| 11.08.2022 | Following the recent playbook, CinCor raises $225M on back of positive PhII readout | On Monday, CinCor Pharma drummed up positive Phase II data for its hypertension drug baxdrostat, following it later that day with a public offering — as many other public biotechs with positive readouts have done with ... |
| 10.08.2022 | Who are the women blazing trails in biopharma R&D? Nominate them for Endpoints' 2022 special report | As public biotechs seek to climb out of the bear market, a popular strategy to raise cash has been through public offerings on the heels of positive data. But one proposed raise Wednesday appeared to take advantage not of a company’s own da... |
| 17.05.2022 | CinCor Pharma to Present at Upcoming Investor Conferences | WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that management will present at the H.C. Wainwright 2022 Global Investment Conference taking place on May 23-26 virtually and in Miami, Flor... |
| 19.04.2022 | CinCor Pharma to Participate in Jefferies Biotech on the Bay Summit | WALTHAM, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) today announced its participation in the Jefferies Biotech on the Bay Summit taking place April 26-27 in Miami, Florida. The CinCor management team will parti... |
| 12.10.2021 | CinCor Pharma Raises $143 Million in Series B Financing | - |
| 12.10.2021 | CinCor Pharma Raises $143 Million in Series B Financing | Funding will support continued development of CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase product candidate, for the treatment of hypertension, primary aldosteronism and chronic kidney disease |
Show more